Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells

References

• Baxter RC, Martin JL. 1986. Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma. J Clin Invest. 78:1504–1512.
   PubMed Web of Science ®Google Scholar
• Benini S, Zuntini M, Manara MC, Cohen P, Nicoletti G, Nanni P, Oh Y, Picci P, Scotlandi K. 2006. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer. 119:1039–1046.
   PubMed Web of Science ®Google Scholar
• Bourhis XL, Toillon RA, Boilly B, Hondermarck H. 2000. Autocrine and paracrine growth inhibitors of breast cancer cells. Breast Cancer Res Treat. 60:251–258.
   PubMed Web of Science ®Google Scholar
• Boyle B, Zhao X, Cohen P, Feldman D. 2001. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol. 165:1319–1324.
   PubMed Web of Science ®Google Scholar
• Burkhart DL, Sage J. 2008. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682.
   PubMed Web of Science ®Google Scholar
• Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, McIntosh J, McCaig C, Winters ZE, Perks CM. 2006. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology. 147:3484–3500.
   PubMed Web of Science ®Google Scholar
• Butt AJ, Firth SM, King MA, Baxter RC. 2000. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 275:39174–39181.
   PubMed Web of Science ®Google Scholar
• Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC. 2004. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: The role of altered epidermal growth factor signaling. J Clin Endocrinol Metab. 89:1950–1956.
   PubMed Web of Science ®Google Scholar
• Chang KH, Chan-Ling T, McFarland EL, Afzal A, Pan H, Baxter LC, Shaw LC, Caballero S, Sengupta N, Li Calzi S, . 2007. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA. 104:10595–10600.
   PubMed Web of Science ®Google Scholar
• Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK. 1990. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: Correlation with estrogen receptor status. Endocrinology. 127:2679–2686.
   PubMed Web of Science ®Google Scholar
• Connell-Crowley L, Harper JW, Goodrich DW. 1997. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 8:287–301.
   PubMed Web of Science ®Google Scholar
• De Leon DD, Bakker B, Wilson DM, Hintz RL, Rosenfeld RG. 1988. Demonstration of insulin-like growth factor (IGF-I and -II) receptors and binding protein in human breast cancer cell lines. Biochem Biophys Res Commun. 152:398–405.
   PubMed Web of Science ®Google Scholar
• De Leon DD, Wilson DM, Powers M, Rosenfeld RG. 1992. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors. 6:327–336.
   PubMed Web of Science ®Google Scholar
• De Mellow JS, Baxter RC. 1988. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun. 156:199–204.
   PubMed Web of Science ®Google Scholar
• Dunn SE, Torres JV, Nihei N, Barrett JC. 2000. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: A new avenue for breast cancer therapy. Mol Carcinog. 27:10–17.
   PubMed Web of Science ®Google Scholar
• Fanayan S, Firth SM, Butt AJ, Baxter RC. 2000. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J Biol Chem. 275:39146–39151.
   PubMed Web of Science ®Google Scholar
• Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. 1993. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem. 52:196–205.
   PubMed Web of Science ®Google Scholar
• Firth SM, Baxter RC. 2002. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 23:824–854.
   PubMed Web of Science ®Google Scholar
• Firth SM, Fanayan S, Benn D, Baxter RC. 1998. Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem Biophys Res Commun. 246:325–329.
   PubMed Web of Science ®Google Scholar
• Firth SM, Ganeshprasad U, Poronnik P, Cook DL, Baxter RC. 1999. Adenoviral-mediated expression of human insulin-like growth factor-binding protein-3. Protein Exp Purif. 16:202–211.
   PubMed Web of Science ®Google Scholar
• Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, Elmlinger MW. 2006. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol. 37:13–23.
   PubMed Web of Science ®Google Scholar
• Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G, Ghidoni R, Ghigo E. 2004. Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: Involvement of the sphingolipid signaling pathways. FASEB J. 18:1456–1458.
   PubMed Web of Science ®Google Scholar
• Granata R, Trovato L, Lupia E, Sala G, Settanni F, Camussi G, Ghidoni R, Ghigo E. 2007. Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost. 5:835–845.
   PubMed Web of Science ®Google Scholar
• Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. 1996. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 56:1545–1550.
   PubMed Web of Science ®Google Scholar
• Gui Y, Murphy LJ. 2001. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): Demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma. J Clin Endocrinol Metab. 86:2104–2110.
   PubMed Web of Science ®Google Scholar
• Harper JW. 2001. Protein destruction: Adapting roles for Cks proteins. Curr Biol. 11:R431–R435.
   Web of Science ®Google Scholar
• Herrera-Gayol A, Jothy S. 2002. Effect of hyaluronan on xenotransplanted breast cancer. Exp Mol Pathol. 72:179–185.
   PubMed Web of Science ®Google Scholar
• Huynh H, Yang X, Pollak M. 1996. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem. 271:1016–1021.
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev. 16:3–34.
   PubMed Web of Science ®Google Scholar
• Katz M, Amit I, Yarden Y. 2007. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 1773:1161–1176.
   PubMed Web of Science ®Google Scholar
• Lee K-W, Liu B, Ma L, Li H, Bang P, Koeffler HP, Cohen P. 2004. Cellular internalization of insulin-like growth factor binding protein-3: Distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem. 279:469–476.
   PubMed Web of Science ®Google Scholar
• Lee EY, Jeon MJ, Yang W, Shin I. 2009. Effect of p27 on motility of MDA-MB-231 breast cancer cells. Oncol Rep. 21:1621–1625.
   PubMed Web of Science ®Google Scholar
• LeRoith D, Roberts CTJr. 2003. The insulin-like growth factor system and cancer. Cancer Lett. 195:127–137.
   PubMed Web of Science ®Google Scholar
• Lester RD, Jo M, Campana WM, Gonias SL. 2005. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem. 280:39273–39277.
   PubMed Web of Science ®Google Scholar
• Liu B, Weinzimer SA, Gibson TB, Mascarenhas D, Cohen P. 2003. Type Iα collagen is an IGFBP-3 binding protein. Growth Horm IGF Res. 13:89–97.
   PubMed Web of Science ®Google Scholar
• Martin JL, Baxter RC. 1999. Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells. J Biol Chem. 274:16407–16411.
   PubMed Web of Science ®Google Scholar
• Martin JL, Coverley JA, Pattison ST, Baxter RC. 1995. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: Stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology. 136:1219–1226.
   PubMed Web of Science ®Google Scholar
• Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen-Duerr P, Klocker H. Novel mechanism of insulin-like growth factor binding protein 3 (IGFBP-3) on prostate cancer cells: Inhibition of proliferation, adhesion and motility. Endocr Relat Cancer. June 9 [Epub ahead of print]. 2009.
   Google Scholar
• McCaig C, Perks CM, Holly JM. 2002. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: Inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci. 115:4293–4303.
   PubMed Web of Science ®Google Scholar
• Mishra S, Raz A, Murphy LJ. 2004. Insulin-like growth factor binding protein-3 interacts with autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and inhibits the AMF/PGI function. Cancer Res. 64:2516–2522.
   PubMed Web of Science ®Google Scholar
• Mu L, Katsaros D, Wiley A, Lu L, de la Longrais IA, Smith S, Khubchandani S, Sochirca O, Arisio R, Yu H. 2009. Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res Treat. 115:151–162.
   PubMed Web of Science ®Google Scholar
• Oh Y, Muller HL, Lamson G, Rosenfeld RG. 1993. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem. 268:14964–14971.
   PubMed Web of Science ®Google Scholar
• Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. 1995. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res. 6:503–512.
   PubMedGoogle Scholar
• Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, . 2006. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther. 5:2685–2695.
   PubMed Web of Science ®Google Scholar
• O'Rear L, Longobardi L, Torello M, Law BK, Moses HL, Chiarelli F, Spagnoli A. 2005. Signaling cross-talk between IGF-binding protein-3 and transforming growth factor-(beta) in mesenchymal chondroprogenitor cell growth. J Mol Endocrinol. 34:723–737.
   PubMed Web of Science ®Google Scholar
• Peng L, Wang J, Malloy PJ, Feldman D. 2008. The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer. 122:558–566.
   PubMed Web of Science ®Google Scholar
• Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM. 1999. Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J Cell Biochem. 75:652–664.
   PubMed Web of Science ®Google Scholar
• Perks CM, McCaig C, Holly JM. 2000. Differential insulin-like growth factor (IGF)-independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria. J Cell Biochem. 80:248–258.
   PubMed Web of Science ®Google Scholar
• Peyrat JP, Bonneterre J, Dusanter-Fourt I, Leroy-Martin B, Djiane J, Demaille A. 1989. Characterization of insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines. Bull Cancer. 76:311–319.
   PubMed Web of Science ®Google Scholar
• Rajah R, Valentinis B, Cohen P. 1997. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 272:12181–12188.
   PubMed Web of Science ®Google Scholar
• Ren Z, Shin A, Cai Q, Shu XO, Gao YT, Zheng W. 2007. IGFBP3 mRNA expression in benign and malignant breast tumors. Breast Cancer Res. 9:R2.
   Web of Science ®Google Scholar
• Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. 1996. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 88:601–606.
   PubMed Web of Science ®Google Scholar
• Samani AA, Yakar S, LeRoith D, Brodt P. 2007. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev. 28:20–47.
   PubMed Web of Science ®Google Scholar
• Seville LL, Shah N, Westwell AD, Chan WC. 2005. Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets. 5:159–170.
   PubMed Web of Science ®Google Scholar
• Shao ZM, Sheikh MS, Ordonez JV, Feng P, Kute T, Chen JC, Aisner S, Schnaper L, LeRoith D, Roberts CTJr, . 1992. IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma. Cancer Res. 52:5100–5103.
   PubMed Web of Science ®Google Scholar
• Sheen-Chen SM, Zhang H, Huang CC, Tang RP. 2009. Insulin-like growth factor-binding protein-3 in breast cancer: Analysis with tissue microarray. Anticancer Res. 29:1131–1135.
   PubMed Web of Science ®Google Scholar
• Sheikh MS, Shao ZM, Clemmons DR, LeRoith D, Roberts CTJr, Fontana JA. 1992. Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells. Biochem Biophys Res Commun. 183:1003–1010.
   PubMed Web of Science ®Google Scholar
• Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW, Lin CT. 2008. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene. 27:2137–2147.
   PubMed Web of Science ®Google Scholar
• Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. 1995. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol. 9:361–367.
   PubMed Web of Science ®Google Scholar
• Xi Y, Nakajima G, Hamil T, Fodstad O, Riker A, Ju J. 2006. Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Mol Cancer Ther. 5:3078–3084.
   PubMed Web of Science ®Google Scholar
• You J, Mi D, Zhou X, Qiao L, Zhang H, Zhang X, Ye L. 2009. A positive feedback between activated extracellularly regulated kinase and cyclooxygenase/lipoxygenase maintains proliferation and migration of breast cancer cells. Endocrinology. 150:1607–1617.
   PubMed Web of Science ®Google Scholar
• Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. 1998. Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer. 79:624–628.
   PubMed Web of Science ®Google Scholar